GU licenses use of tyrosine kinase inhibitors for treatment of neurodegenerative diseases

(Georgetown University Medical Center) Georgetown University today announces it has exclusively licensed worldwide intellectual property (IP) rights to develop and commercialize uses of tyrosine kinase (TK) inhibitors for the treatment of neurodegenerative diseases to Axovant Sciences GmbH.